Single oral doses in mice and rats resulted in mortality and/or moribundity at doses of 600 mg/kg and 500 mg/kg, respectively. Single intraperitoneal doses in mice and rats results in mortality/moribundity at 750 mg/kg and 1000 mg/kg, respectively. The maximum non-lethal single oral and intraperitoneal dose in mouse was 300 mg/kg and 250 mg/kg, respectively. In the rat it was 150 mg/kg and 250 mg/kg, respectively.
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Amlodipine | The metabolism of Lumiracoxib can be decreased when combined with Amlodipine. |
| Phentermine | The risk or severity of hypertension can be increased when Phentermine is combined with Lumiracoxib. |
| Midodrine | The risk or severity of hypertension can be increased when Midodrine is combined with Lumiracoxib. |
| Isoetharine | The risk or severity of hypertension can be increased when Isoetharine is combined with Lumiracoxib. |
| Ziprasidone | The risk or severity of hypertension can be increased when Ziprasidone is combined with Lumiracoxib. |
| Methysergide | The risk or severity of hypertension can be increased when Methysergide is combined with Lumiracoxib. |
| Cabergoline | The risk or severity of hypertension can be increased when Cabergoline is combined with Lumiracoxib. |
| Zolmitriptan | The risk or severity of hypertension can be increased when Zolmitriptan is combined with Lumiracoxib. |
| Dihydroergotamine | The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Lumiracoxib. |
| Methylergometrine | The risk or severity of hypertension can be increased when Methylergometrine is combined with Lumiracoxib. |
| Norepinephrine | The risk or severity of hypertension can be increased when Norepinephrine is combined with Lumiracoxib. |
| Mirtazapine | The risk or severity of hypertension can be increased when Mirtazapine is combined with Lumiracoxib. |
| Phenylephrine | The risk or severity of hypertension can be increased when Phenylephrine is combined with Lumiracoxib. |
| Phenylpropanolamine | The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Lumiracoxib. |
| Droperidol | The risk or severity of hypertension can be increased when Droperidol is combined with Lumiracoxib. |
| Doxapram | The risk or severity of hypertension can be increased when Doxapram is combined with Lumiracoxib. |
| Atropine | The risk or severity of hypertension can be increased when Atropine is combined with Lumiracoxib. |
| Lisuride | The risk or severity of hypertension can be increased when Lisuride is combined with Lumiracoxib. |
| Linezolid | The risk or severity of hypertension can be increased when Linezolid is combined with Lumiracoxib. |
| Metaraminol | The risk or severity of hypertension can be increased when Metaraminol is combined with Lumiracoxib. |
| Furazolidone | The risk or severity of hypertension can be increased when Furazolidone is combined with Lumiracoxib. |
| Thioridazine | The risk or severity of hypertension can be increased when Thioridazine is combined with Lumiracoxib. |
| Ergotamine | The risk or severity of hypertension can be increased when Ergotamine is combined with Lumiracoxib. |
| Nicergoline | The risk or severity of hypertension can be increased when Nicergoline is combined with Lumiracoxib. |
| Sufentanil | The risk or severity of hypertension can be increased when Sufentanil is combined with Lumiracoxib. |
| Methoxamine | The risk or severity of hypertension can be increased when Methoxamine is combined with Lumiracoxib. |
| Risperidone | The risk or severity of hypertension can be increased when Risperidone is combined with Lumiracoxib. |
| Isoflurane | The risk or severity of hypertension can be increased when Isoflurane is combined with Lumiracoxib. |
| Propiomazine | The risk or severity of hypertension can be increased when Propiomazine is combined with Lumiracoxib. |
| Alfentanil | The risk or severity of hypertension can be increased when Alfentanil is combined with Lumiracoxib. |
| Minaprine | The risk or severity of hypertension can be increased when Minaprine is combined with Lumiracoxib. |
| Orciprenaline | The risk or severity of hypertension can be increased when Orciprenaline is combined with Lumiracoxib. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Lumiracoxib. |
| Trifluoperazine | The risk or severity of hypertension can be increased when Trifluoperazine is combined with Lumiracoxib. |
| Pseudoephedrine | The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lumiracoxib. |
| Benzphetamine | The risk or severity of hypertension can be increased when Benzphetamine is combined with Lumiracoxib. |
| Ritodrine | The risk or severity of hypertension can be increased when Ritodrine is combined with Lumiracoxib. |
| Flupentixol | The risk or severity of hypertension can be increased when Flupentixol is combined with Lumiracoxib. |
| Remifentanil | The risk or severity of hypertension can be increased when Remifentanil is combined with Lumiracoxib. |
| Bitolterol | The risk or severity of hypertension can be increased when Bitolterol is combined with Lumiracoxib. |
| Oxymetazoline | The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lumiracoxib. |
| Diethylpropion | The risk or severity of hypertension can be increased when Diethylpropion is combined with Lumiracoxib. |
| Salmeterol | The risk or severity of hypertension can be increased when Salmeterol is combined with Lumiracoxib. |
| Naratriptan | The risk or severity of hypertension can be increased when Naratriptan is combined with Lumiracoxib. |
| Frovatriptan | The risk or severity of hypertension can be increased when Frovatriptan is combined with Lumiracoxib. |
| Ergoloid mesylate | The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Lumiracoxib. |
| Isoprenaline | The risk or severity of hypertension can be increased when Isoprenaline is combined with Lumiracoxib. |
| Arbutamine | The risk or severity of hypertension can be increased when Arbutamine is combined with Lumiracoxib. |
| Dutasteride | The risk or severity of hypertension can be increased when Dutasteride is combined with Lumiracoxib. |
| Pergolide | The risk or severity of hypertension can be increased when Pergolide is combined with Lumiracoxib. |
| Desflurane | The risk or severity of hypertension can be increased when Desflurane is combined with Lumiracoxib. |
| Bromocriptine | The risk or severity of hypertension can be increased when Bromocriptine is combined with Lumiracoxib. |
| Finasteride | The risk or severity of hypertension can be increased when Finasteride is combined with Lumiracoxib. |
| Aripiprazole | The risk or severity of hypertension can be increased when Aripiprazole is combined with Lumiracoxib. |
| Isocarboxazid | The risk or severity of hypertension can be increased when Isocarboxazid is combined with Lumiracoxib. |
| Ergometrine | The risk or severity of hypertension can be increased when Ergometrine is combined with Lumiracoxib. |
| Lisdexamfetamine | The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Lumiracoxib. |
| Fenoterol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Fenoterol. |
| Pirbuterol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Pirbuterol. |
| Ephedra sinica root | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Ephedra sinica root. |
| Ephedrine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Ephedrine. |
| Mephentermine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Mephentermine. |
| Procaterol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Procaterol. |
| Yohimbine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Yohimbine. |
| Methotrimeprazine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Methotrimeprazine. |
| Clenbuterol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Clenbuterol. |
| Bambuterol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Bambuterol. |
| MMDA | The risk or severity of hypertension can be increased when Lumiracoxib is combined with MMDA. |
| Midomafetamine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Midomafetamine. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with 2,5-Dimethoxy-4-ethylamphetamine. |
| 4-Methoxyamphetamine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with 4-Methoxyamphetamine. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with 4-Bromo-2,5-dimethoxyamphetamine. |
| Tenamfetamine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Tenamfetamine. |
| Chlorphentermine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Chlorphentermine. |
| Dextroamphetamine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Dextroamphetamine. |
| Phendimetrazine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Phendimetrazine. |
| Solifenacin | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Solifenacin. |
| Periciazine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Periciazine. |
| Acepromazine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Acepromazine. |
| Thioproperazine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Thioproperazine. |
| Zuclopenthixol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Zuclopenthixol. |
| Epicaptopril | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Epicaptopril. |
| Clorgiline | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Clorgiline. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when Lumiracoxib is combined with 1-benzylimidazole. |
| Nialamide | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Nialamide. |
| Lysergic acid diethylamide | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Lysergic acid diethylamide. |
| Dronedarone | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Dronedarone. |
| Flibanserin | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Flibanserin. |
| Iloperidone | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Iloperidone. |
| Indacaterol | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Indacaterol. |
| Rotigotine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Rotigotine. |
| Amibegron | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Amibegron. |
| Naluzotan | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Naluzotan. |
| Cariprazine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Cariprazine. |
| Mianserin | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Mianserin. |
| Pizotifen | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Pizotifen. |
| Solabegron | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Solabegron. |
| Asenapine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Asenapine. |
| Esmirtazapine | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Esmirtazapine. |
| Vilazodone | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Vilazodone. |